Common Patient Groups that Experience a Biochemical Incomplete Response in the Context of Dynamic Risk Stratification for Differentiated Thyroid Cancer (DTC)

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Common patient groups that experience a biochemical incomplete response in the context of dynamic risk stratification for differentiated thyroid cancer (DTC) include:
  • Low-Risk Patients:
    • Approximately 11% to 19% of patients initially classified as low-risk by the American Thyroid Association (ATA) experience a biochemical incomplete response
    • These patients typically have persistently abnormal thyroglobulin (Tg) values or rising anti-Tg antibodies without structural evidence of disease
  • Intermediate-Risk Patients:
    • This group has a higher incidence, with 21% to 22% of patients experiencing a biochemical incomplete response
    • These patients often have more aggressive disease features, such as larger tumor size or lymph node involvement, which contribute to the incomplete biochemical response
  • High-Risk Patients:
    • Even among high-risk patients, 16% to 18% experience a biochemical incomplete response
    • These patients are more likely to have advanced disease at diagnosis, including distant metastases or extensive lymph node involvement
  • Patients with BRAFV600E Mutation:
    • The presence of the BRAFV600E mutation is significantly associated with a biochemical incomplete response
    • This mutation is linked to more aggressive disease and a higher likelihood of persistent biochemical evidence of disease
  • Patients with Higher Preablative Stimulated Tg Levels:
    • Patients with higher preablative stimulated Tg levels (≥ 12.30 ng/mL) are more likely to experience a biochemical incomplete response
    • This marker is a robust predictor of persistent disease
  • These groups highlight the variability in response to initial therapy and underscore the importance of dynamic risk stratification in guiding follow-up and management strategies for DTC patients
  • References:
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment